`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`
`LIQUIDIA TECHNOLOGIES, INC.,
`
`Petitioner
`
`v.
`
`UNITED THERAPEUTICS CORPORATION,
`
`Patent Owner.
`
`_______________
`
`Case IPR2020-00770
`Patent No. 9,604,901
`
`_______________
`
`____________________________________________________________
`
`Patent Owner’s Updated Mandatory Notices
`Under 37 C.F.R. § 42.8
`
`4843-8379-0016.1
`
`
`
`IPR2020-00770
`U.S. Patent No. 9,604,901
`
`
`Patent Owner Updated Mandatory Notices
`
`
`Pursuant to 37 C.F.R. § 42.8, United Therapeutics Corporation (“United
`
`Therapeutics”) provides this Updated Mandatory Notice.
`
`I.
`
`Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8 (b)(1):
`
`United Therapeutics is the sole owner of U.S. Patent No. 9,604,901 (the
`
`“’901 patent”).
`
`II. Related Matters Pursuant to 37 C.F.R. § 42.8 (b)(2):
`
`US Ser. No. 16/594,737 is a pending continuation application with common
`
`priority to the ’901 patent. IPR2020-00769 involves U.S. Patent No. 9,593,066
`
`(the “’066 patent”), a patent with common priority to the ’901 patent.
`
`On June 4, 2020, United Therapeutics filed a lawsuit in the U.S. District
`
`Court for the District of Delaware against Liquidia Technologies for infringement
`
`of the ’901 and ’066 patents: United Therapeutics Corporation v. Liquidia
`
`Technologies, Inc., Case No. 1:20-cv-00755-RGA (D. Del.).
`
`United Therapeutics is not aware of any other related matters involving the
`
`’901 patent.
`
`III. Lead and Back-Up Counsel Pursuant to 37 C.F.R. §§ 42.8(b)(3):
`
`United Therapeutics designates the following Lead and Back-up Counsel:
`
`4843-8379-0016.1
`
`1
`
`
`
`Patent Owner Updated Mandatory Notices
`
`
`IPR2020-00770
`U.S. Patent No. 9,604,901
`
`
`Lead Counsel:
`
`Stephen B. Maebius
`Foley & Lardner LLP
`3000 K St., NW, Suite 600
`Washington, DC 20007
`Direct Line: 202-672-5569
`Email: smaebius@foley.com
`Fax: 202-672-5399
`USPTO Reg. No. 35,264
`
`Backup Counsel:
`
`George Quillin
`Foley & Lardner LLP
`3000 K St., NW, Suite 600
`Washington, DC 20007
`Direct Line: 202-672-5413
`Email: gquillin@foley.com
`Fax: 202-672-5399
`USPTO Reg. No. 32,792
`
`Daniel R. Shelton
`Foley & Lardner LLP
`975 Page Mill Rd.
`Palo Alto, CA 94304
`Direct Line: 650-251-1119
`Email: dshelton@foley.com
`Fax: 650-856-3710
`USPTO Reg. No. 68,519
`
`
`
`
`
`4843-8379-0016.1
`
`2
`
`
`
`IPR2020-00770
`U.S. Patent No. 9,604,901
`
`
`Patent Owner Updated Mandatory Notices
`
`
`Shaun R. Snader
`United Therapeutics Corp.
`1735 Connecticut Ave., NW, 2nd Floor
`Washington, DC 20009
`Direct Line: 202-304-1701
`Email: ssnader@unither.com
`USPTO Reg. No. 59,987
`
`Douglas Carsten
`Wilson, Sonsini, Goodrich & Rosati
`12235 El Camino Real
`Suite 200
`San Diego, CA 92130
`Direct Line: 858-350-2305
`Email: dcarsten@wsgr.com
`Fax: 858-350-2399
`USPTO Reg. No. 43,534
`
`Richard Torczon
`Wilson, Sonsini, Goodrich & Rosati
`1700 K Street NW, Floor 5
`Washington, DC 20006
`Direct Line: 202-973-8811
`Email: rtorczon@wsgr.com
`Fax: 202-973-8899
`USPTO Reg. No. 34,448
`
`
`
`IV. Service Information Pursuant to 37 C.F.R. §§ 42.8(b)(4):
`
`Please address all correspondence to the lead counsel at the address shown
`
`above. Patent Owner consents to electronic service by e-mail at:
`
`smaebius@foley.com and UTC-901@foley.com
`
`Any questions concerning this paper may be directed to lead counsel.
`3
`
`4843-8379-0016.1
`
`
`
`IPR2020-00770
`U.S. Patent No. 9,604,901
`
`
`
`
`Patent Owner Updated Mandatory Notices
`
`
`Dated: June 16, 2020
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
`Counsel for Patent Owner
`
`
`
`4843-8379-0016.1
`
`4
`
`
`
`IPR2020-00770
`U.S. Patent No. 9,604,901
`
`
`Patent Owner Updated Mandatory Notices
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing United
`
`Therapeutics Corporation’s Updated Mandatory Notices Under 37 C.F.R.
`
`§ 42.8 was served on June 16, 2020, by email directed to the attorneys of record for
`
`the Petitioner at the following addresses:
`
`zLiquidiaIPR@cooley.com1
`ielrifi@cooley.com
`emilch@cooley.com
`dkannappan@cooley.com
`
`By: /Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
`Counsel for Patent Owner
`
`
`
`
`
`
`
`
`Dated: June 16, 2020
`
`
`
`
`
`
`
`1 Patent Owner notes that this email address is listed in the petition filed against the
`
`’066 patent but not in the petition filed against the ’901 patent.
`
`4843-8379-0016.1
`
`